Rocket Pharmaceuticals, Inc. – NASDAQ:RCKT

Add to watchlist

$2.97

-8.78

-74.72%

Market closed

Open in about 14 hours

-47.78%

month

-47.78%

quarter

-63.21%

year

Market Cap	1.20B
Enterprise value	1.04B

P/E	-5.52
EV/Sales	N/A
EV/EBITDA	-4.87
Price/Sales	N/A
Price/Book	2.36
PEG ratio	0.24
EPS	-2.86

Revenue	N/A
EBITDA	-251.30M
Income	-249.31M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Rocket Pharmaceuticals Stock Forecast

M Q Y

Last Year

$40.67

Potential upside: 1269.24%

Analysts Price target
Financials & Ratios estimates

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT): Profit margin
Jun 2023	0	-65.70M
Sep 2023	0	-61.89M
Dec 2023	10.31M	-59.66M	-578.55%
Mar 2024	0	-62.05M

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT): Debt to assets
Jun 2023	461781000	58.81M	12.74%
Sep 2023	598762000	57.67M	9.63%
Dec 2023	566341000	73.76M	13.03%
Mar 2024	499442000	57.94M	11.6%

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT): Cash Flow
Jun 2023	-50.86M	31.20M	182K
Sep 2023	-57.14M	48.25M	189.48M
Dec 2023	-29.33M	-140.80M	391K
Mar 2024	-56.88M	35.03M	1.21M

Rocket Pharmaceuticals alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Rocket Pharmaceuticals
Employees

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT): Employee count
Aug 2023	240
Sep 2023	240
Oct 2023	240
Nov 2023	240
Dec 2023	240
Jan 2024	240
Feb 2024	240
Mar 2024	268
Apr 2024	268
May 2024	268
Jun 2024	268
Jul 2024	268

Rocket Pharmaceuticals
Hedge Funds Holdings Q1 2023

66.26% -33.74%

of RCKT is owned by hedge funds

100 -65

hedge funds hold RCKT stock

45.15M -30.71M

shares is hold by hedge funds

RCKT hedge funds holdings changes

Rocket Pharmaceuticals
Insider Trading

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT): Insider trades (number of shares)
Period	Buy	Sel
Jan 2024	0	638
Feb 2024	0	48318
Mar 2024	0	276490
Apr 2024	0	93365
May 2024	0	15963
Jul 2024	0	3838
Aug 2024	0	15730
Oct 2024	0	3997
Nov 2024	0	18078

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	21 Nov 2024	MILITELLO JOHN officer: See Remarks officer: See Remarks	Common Stock	1,224	$13.05	$15,978
Sale	21 Nov 2024	PATEL KINNARI officer: See Remarks officer: See Remarks	Common Stock	4,588	$13.05	$59,892
Sale	21 Nov 2024	SHAH GAURAV director, officer..	Common Stock	11,091	$13.05	$144,782
Sale	21 Nov 2024	WILSON MARTIN officer: General Counsel officer: General Counsel	Common Stock	1,175	$13.05	$15,338
Sale	31 Oct 2024	WHITE MARK ANDREW officer: See Remarks officer: See Remarks	Common Stock	3,080	$16.63	$51,205
Sale	31 Oct 2024	MILITELLO JOHN officer: See Remarks officer: See Remarks	Common Stock	917	$16.63	$15,245
Sale	16 Aug 2024	MILITELLO JOHN officer: See Remarks officer: See Remarks	Common Stock	1,064	$18.5	$19,688
Sale	16 Aug 2024	PATEL KINNARI officer: See Remarks officer: See Remarks	Common Stock	3,989	$18.5	$73,812
Sale	16 Aug 2024	SHAH GAURAV director, officer..	Common Stock	9,650	$18.5	$178,564
Sale	16 Aug 2024	WILSON MARTIN officer: General Counsel officer: General Counsel	Common Stock	1,027	$18.5	$19,004

RCKT insider trading transactions

Rocket Pharmaceuticals
Earnings Call Transcripts

Quarter	Transcript
Q2 2021 9 Aug 2021	Q2 2021 Earnings Call Transcript

RCKT earnings call transcripts

Rocket Pharmaceuticals
Executives

Insider	Age	Compensation
Dr. Gaurav D. Shah (1975) Chief Executive Officer & Director	50	$1,040,000
Ms. Kinnari Patel M.B.A., Pharm.D., PharmD, MBA (1979) Pres, Chief Operating Officer & Head of Devel.	46	$825,900
Mr. Jonathan Schwartz (1964) Chief Medical Officer & Senior Vice President of Clinical Devel.	61	$619,700
Mr. John C. Militello CPA, CPA (1973) Vice President, Senior Controller & Principal Accounting Officer	52	$385,780

Rocket Pharmaceuticals
Latest News

Wednesday, 18 December 2024
15:00	Rocket Pharmaceuticals Stock Soars as Jefferies Initiates Coverage at 'Buy'	investopedia.com
Tuesday, 10 December 2024
16:01	Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock	businesswire.com
Wednesday, 27 November 2024
08:06	3 Small-Cap Stocks That Are Ready to Rocket Higher	marketbeat.com
Tuesday, 26 November 2024
07:00	Rocket Pharmaceuticals to Participate in the 7th Annual Evercore HealthCONx Conference	businesswire.com
Tuesday, 19 November 2024
14:47	Rocket Pharmaceuticals' Gene Therapy Progress Boosts Confidence in Future Developments: Analyst	benzinga.com
Monday, 18 November 2024
11:00	Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association Conference	businesswire.com
Tuesday, 12 November 2024
16:01	Rocket Pharmaceuticals to Present Updated Data from the Phase 1 Clinical Trial of RP-A501 for Danon Disease at the American Heart Association's 2024 Late-Breaking Science Sessions	businesswire.com
Monday, 11 November 2024
11:10	Rocket Pharmaceuticals' Q3 Earnings Beat, Pipeline in Focus	zacks.com
09:11	Rocket Pharmaceuticals price target raised to $51 from $50 at Scotiabank	https://thefly.com
Friday, 8 November 2024
07:00	Rocket Pharmaceuticals to Participate in the UBS Global Healthcare Conference	businesswire.com
Thursday, 19 September 2024
15:18	Rocket: Danon Disease Treatment Program Should Carry The Tide Until Regulatory Moves	seekingalpha.com
Wednesday, 18 September 2024
11:50	RCKT Completes Enrollment in Rare Heart Disease Study, Stock Rises	zacks.com
Monday, 9 September 2024
12:05	Rocket Stock Down More Than 30% in Past Six Months: Here's Why	zacks.com
Monday, 29 July 2024
15:32	3 Biotech Names With Potential Catalysts By Year End	seekingalpha.com
Tuesday, 2 July 2024
05:11	FDA Rejects Rocket's (RCKT) Gene Therapy BLA for Rare Disease	zacks.com
Friday, 28 June 2024
13:26	FDA Again Delays Approval of Rocket Pharmaceuticals' Gene Therapy Treatment	investopedia.com
07:27	Rocket Pharmaceuticals Provides Regulatory Update on KRESLADI™ (marnetegragene autotemcel; marne-cel)	businesswire.com
Wednesday, 5 June 2024
12:35	Why Is Rocket Pharmaceuticals (RCKT) Down 4.8% Since Last Earnings Report?	zacks.com
Wednesday, 29 May 2024
07:00	Rocket Pharmaceuticals Receives Orphan Medicinal Product Designation from the European Commission for RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy	businesswire.com
Friday, 10 May 2024
06:00	Rocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)	businesswire.com
Tuesday, 7 May 2024
12:31	Rocket's (RCKT) Q1 Loss Narrower Than Expected, Sales Nil	Zacks Investment Research
Tuesday, 30 April 2024
13:00	Rocket Pharmaceuticals (RCKT) Upgraded to Buy: Here's Why	Zacks Investment Research
Friday, 5 April 2024
11:50	Rocket Pharmaceuticals: Cautiously Optimistic (Rating Upgrade)	Seeking Alpha
Wednesday, 3 April 2024
12:36	EMA Accepts Rocket (RCKT) Gene Therapy Filing for Fanconi Anemia	Zacks Investment Research
Tuesday, 2 April 2024
14:34	Rocket Pharmaceuticals: Multiple Regulatory Submissions Make It A Must Watch	Seeking Alpha
Wednesday, 27 March 2024
12:36	Why Is Rocket Pharmaceuticals (RCKT) Down 13.6% Since Last Earnings Report?	Zacks Investment Research
Friday, 1 March 2024
18:03	Rocket Pharmaceuticals' Promising Path In Gene Therapy	Seeking Alpha
Tuesday, 27 February 2024
13:21	Rocket (RCKT) Registers Narrower-Than-Expected Loss in Q4	Zacks Investment Research
Monday, 22 January 2024
22:14	7 Speculative Stocks to Double Your Money THIS Year	InvestorPlace
Wednesday, 15 November 2023
12:47	Rocket (RCKT) Surges 40% in 3 Months on Regulatory Updates	Zacks Investment Research

Ideas & Opinions

Seeking Alpha 10 Apr 2025

Rocket Pharmaceuticals Out Of Orbit, But Ready For Relaunch
Seeking Alpha 5 Apr 2024

Rocket Pharmaceuticals: Cautiously Optimistic (Rating Upgrade)
Seeking Alpha 2 Apr 2024

Rocket Pharmaceuticals: Multiple Regulatory Submissions Make It A Must Watch
Seeking Alpha 21 Sep 2023

Rocket Pharmaceuticals: Update On RP-A501 Strengthens Bullish Outlook
Seeking Alpha 14 Sep 2023

Rocket Pharmaceuticals: Soaring On Pivotal Danon Disease Study Agreement - More Upside Ahead?
Seeking Alpha 3 Aug 2023

Rocket Pharmaceuticals: Thriving Gene Therapy With Multiple Catalysts
Seeking Alpha 11 May 2023

Rocket Pharmaceuticals: A Catalyst-Rich Year Ahead
Seeking Alpha 16 Feb 2023

Rocket Pharmaceuticals: Promising Gene Therapy Play With Discounted Entry Point
Seeking Alpha 16 Feb 2023

Rocket Pharmaceuticals Has A Lot More Upside
Seeking Alpha 29 Nov 2022

Rocket Pharmaceuticals: 2 Regulatory Filings In 2023 Could Propel It Higher

Frequently Asked Questions (FAQ)

What's the price of Rocket Pharmaceuticals stock today?

One share of Rocket Pharmaceuticals stock can currently be purchased for approximately $2.97.
When is Rocket Pharmaceuticals's next earnings date?

Unfortunately, Rocket Pharmaceuticals's (RCKT) next earnings date is currently unknown.
Does Rocket Pharmaceuticals pay dividends?

No, Rocket Pharmaceuticals does not pay dividends.
How much money does Rocket Pharmaceuticals make?

Rocket Pharmaceuticals has a market capitalization of 1.20B.
What is Rocket Pharmaceuticals's stock symbol?

Rocket Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "RCKT".
What is Rocket Pharmaceuticals's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Rocket Pharmaceuticals?

Shares of Rocket Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Rocket Pharmaceuticals's key executives?
Rocket Pharmaceuticals's management team includes the following people:
- Dr. Gaurav D. Shah Chief Executive Officer & Director(age: 50, pay: $1,040,000)
- Ms. Kinnari Patel M.B.A., Pharm.D., PharmD, MBA Pres, Chief Operating Officer & Head of Devel.(age: 46, pay: $825,900)
- Mr. Jonathan Schwartz Chief Medical Officer & Senior Vice President of Clinical Devel.(age: 61, pay: $619,700)
- Mr. John C. Militello CPA, CPA Vice President, Senior Controller & Principal Accounting Officer(age: 52, pay: $385,780)
How many employees does Rocket Pharmaceuticals have?

As Jul 2024, Rocket Pharmaceuticals employs 268 workers.
When Rocket Pharmaceuticals went public?

Rocket Pharmaceuticals, Inc. is publicly traded company for more then 10 years since IPO on 18 Feb 2015.
What is Rocket Pharmaceuticals's official website?

The official website for Rocket Pharmaceuticals is rocketpharma.com.
Where are Rocket Pharmaceuticals's headquarters?

Rocket Pharmaceuticals is headquartered at 9 Cedarbrook Drive, Cranbury, NJ.
How can i contact Rocket Pharmaceuticals?

Rocket Pharmaceuticals's mailing address is 9 Cedarbrook Drive, Cranbury, NJ and company can be reached via phone at +60 9 659 8001.
What is Rocket Pharmaceuticals stock forecast & price target?

Based on 2 Wall Street analysts` predicted price targets for Rocket Pharmaceuticals in the last 12 months, the avarage price target is $40.67. The average price target represents a 1269.24% change from the last price of $2.97.

Rocket Pharmaceuticals, Inc.

rocketpharma.com

Exchange:

NASDAQ

Full time employees:

268

Industry:

Biotechnology

Sector:

Healthcare

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.

+60 9 659 8001

9 Cedarbrook Drive
Cranbury, NJ 08512

CIK: 0001281895
ISIN: US77313F1066
CUSIP: 77313F106